Tracer library / [225Ac]Ac-225-DOTA-J591

[225Ac]Ac-225-DOTA-J591

Also written as Ac-225-DOTA-J591

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 0

Prostate cancer PSMA-directed radioligand therapy

What it is

Compound class: Radiolabeled monoclonal antibody (DOTA-conjugated anti-PSMA antibody, J591)
Target / mechanism: Prostate-specific membrane antigen (PSMA), extracellular epitope PMID 37163648
Clinical application: Prostate cancer PMID 37163648
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [225Ac]Ac-225-DOTA-J591, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37163648: 'DOTA-J591'. Stage set/updated at stage 39 from PMID 37163648: 'which is currently being studied in early clinical trials'.